Cabot (NYSE:CBT – Get Free Report) issued an update on its FY25 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $7.40-7.80 for the period, compared to the consensus estimate of $7.85. Cabot also updated its FY 2025 guidance to 7.400-7.800 EPS.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on CBT shares. JPMorgan Chase & Co. lifted their price target on Cabot from $95.00 to $105.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. UBS Group reduced their price objective on shares of Cabot from $103.00 to $98.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 6th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $101.75.
Check Out Our Latest Analysis on CBT
Cabot Stock Up 1.0 %
Cabot (NYSE:CBT – Get Free Report) last announced its earnings results on Monday, August 5th. The specialty chemicals company reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Cabot had a net margin of 12.05% and a return on equity of 26.99%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.42 earnings per share. Equities research analysts predict that Cabot will post 7.07 earnings per share for the current fiscal year.
Insider Activity
In related news, CFO Erica Mclaughlin sold 23,274 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $99.79, for a total value of $2,322,512.46. Following the sale, the chief financial officer now directly owns 59,814 shares in the company, valued at approximately $5,968,839.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Erica Mclaughlin sold 23,274 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $99.79, for a total value of $2,322,512.46. Following the sale, the chief financial officer now owns 59,814 shares in the company, valued at approximately $5,968,839.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Sean D. Keohane sold 25,617 shares of Cabot stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $101.55, for a total value of $2,601,406.35. Following the sale, the chief executive officer now owns 331,174 shares of the company’s stock, valued at approximately $33,630,719.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,939 shares of company stock valued at $7,308,812 in the last 90 days. Insiders own 3.07% of the company’s stock.
About Cabot
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Further Reading
- Five stocks we like better than Cabot
- Using the MarketBeat Dividend Tax Calculator
- Intel: Is Now the Time to Be Brave?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Ride Out The Recession With These Dividend Kings
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.